OVERVIEW

The Myeloid Malignancy Workshop will be a one day hybrid event focused on the science and medicine of myelodysplastic syndromes, myeloproliferative neoplasms, and acute myeloid leukemia. The workshop will include internationally recognized clinical and laboratory experts in the field that will provide focused talks intended to highlight the cutting edge science and recent evidence based advances in clinical care of myeloid malignancies.

TARGET AUDIENCE

Specialties - Academic/Research, Genomic Medicine, Geriatric Medicine, Hematology, Internal Medicine, Multiple Specialties, Nurse Practitioner, Nursing, Oncology, Pathology, Pharmacist, Physician Assistant

LEARNING OBJECTIVES

1. Understand the molecular and immunologic vulnerabilities driving drug development for MDS, MPN and AML
2. Select the appropriate evidence based therapies for patients with myeloid malignancies
3. Recognize the remaining unmet needs in treating myeloid malignancies.
4. Identify the appropriate patients with myelofibrosis and myelodysplastic syndromes for hematopoietic stem cell transplantation
5. Discuss strategies to incorporate disease-modifying therapies and strive for deeper responses in patients with myeloproliferative neoplasms
6. Discuss the emerging results of clinical trials that are investigating therapies in AML/MDS
7. Identify treatment goals for systemic mastocytosis that incorporate next generation kit inhibitors.

ACCREDITATION

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (9.00 hours)

For more information please visit the official event page.